Layoff
May 2026After the ALS asset failed and the company rebranded as Verge Labs, reporting indicated Verge cut about 90% of its workforce and pivoted to a leaner platform-first model.
SourceWe use human data and AI to develop better drugs faster.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Verge Genomics, now publicly operating as Verge Labs, is a 2015-founded San Francisco biotech/AI company focused on precision neurology and AI-driven drug discovery using its proprietary CONVERGE platform and multimodal human brain data.
Primary product
CONVERGE® all-in-human drug discovery / precision neurology platform (including vBx-1.0)
Founded
2015
Headquarters
San Francisco, California, United States
Team size
10-20
Work style
Flexible
Industry
Biotechnology Research
Sub-industry
AI-driven drug discovery and precision neurology
Offices
455 Market St., Ste 1940, PMB 805233, San Francisco, CA 94105
South San Francisco, California, United States (131 Oyster Point Blvd #300 reported by business profiles)
Business model
B2B platform licensing
strategic pharma/biotech collaborations
clinical-stage therapeutic development
Funding
Stage
Series C
Total raised
$176.1M
Latest round
Series C · Oct 2024
Oct 2024
Corporate minority / strategic equity collaboration
Sep 2023 · AstraZeneca / Alexion
Dec 2021 · BlackRock
Oct 2020
Jul 2018 · DFJ
Nov 2015 · IA Ventures
People & investors
Leadership
CEO & Co-founder
Vice President, Operations
Vice President, Product and Engineering
Chief Business Officer
Co-founder
Non-Executive Director and Co-Founder
Work & culture
Public materials emphasize courageous ambition, radical candor, taking 100% responsibility, diversity, and a founder-led high-ownership culture; employee comments also highlight candor and calculated risk-taking.
Work style
Flexible
Compensation
Public job postings and career pages signal competitive compensation, equity, and annual bonus eligibility; at least one posted US role showed a base salary band of about $131.5k-$156.5k.
Benefits
equity
annual performance bonus
medical insurance
dental insurance
vision insurance
401(k) with employer matching
unlimited paid time off
paid holidays
paid sick days
generous parental leave
free onsite fitness center
free snacks and drinks
free lunch
WFH stipend for remote employees
Product & market
Pricing
Platform licensing / co-development contracts with upfront fees, equity, milestone payments, and royalties
Differentiators
- —proprietary multimodal human brain dataset spanning 12,000+ brains and 6,000+ patients
- —all-in-human CONVERGE platform trained on patient tissue rather than animal models
- —virtual biopsy / precision neurology models that predict response and trial enrichment
- —83% preclinical validation rate for prioritized targets
- —experience taking AI-discovered assets into clinical testing
- —platform-first commercial model for partner drug developers
Technology
Python
GitHub
PyTorch
NumPy
Apache Spark
PostgreSQL
Docker
Kubernetes
Django
Redis
SQL
Linux
C
Customers
Eli Lilly
Alexion / AstraZeneca Rare Disease
Ferrer
Tenacia Biotechnology
pharma and biotech partners seeking CNS target discovery, patient stratification, and biomarker prediction
Competitors
Isomorphic Laboratories
Insilico Medicine
BioMap
Insitro
Valo Health
AQEMIA
Atomwise / Numerion Labs
Alector
Denali Therapeutics
Deep Genomics
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
4.2K
Traffic estimate as of Apr 2026
Signals & risks
Other
Dec 2025Verge’s sole clinical candidate, VRG50635, failed efficacy in a Phase 1b ALS trial and the company stopped advancing the program.
SourceLatest news
STAT · Jun 2026
STAT reported on Verge Labs’ vBx-1.0 launch and how the model is intended to improve patient stratification and trial design in neurology.
PR Newswire · Jun 2026
Official launch of vBx-1.0, a precision neurology foundation model and virtual biopsy product.
PR Newswire · Jun 2026
Verge announced its first partnership under the new platform-first commercial model.
PR Newswire · May 2026
Verge Genomics rebranded publicly as Verge Labs and described the shift from in-house therapeutics to a platform-first AI lab.
GlobeNewswire · Nov 2024
Lilly selected two validated ALS targets from Verge’s CONVERGE collaboration, triggering milestone payments.
Jobs and careers at Verge Genomics
0 jobs at Verge Genomics
No open positions
Check back later for new openings